Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 182

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 182
---
, such as Adaptive Therapeutics, Inc., Immatics, N.V., 3T Biosciences, Inc., and Sana Biotechnology, Inc.,
among others. We may also compete against a significant number of companies engaged in the development of autologous and allogeneic CAR-
T, CAR-NK, TIL and T cell engager technologies including larger companies such as Gilead Sciences, Inc., Bristol-Myers Squibb Company
and Amgen, Inc. as well as smaller companies such as Nkarta Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., and Fate Therapeutics
Inc., among others.

Many of our competitors,
either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise
in R&D, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisitions activity in the pharmaceutical,
biopharmaceutical, and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors.
Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements
with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, and acquiring technologies complementary to, or necessary
for, our programs.

Our commercial opportunity
could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better
tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position
to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before
we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety,
efficacy, convenience, and treatment cost.

<div align='center'>107</div>

In the event we receive
regulatory approval for any of our product candidates, we will likely compete with other cost-effective and reimbursable treatments used
to treat cancer. The most common treatment modalities for patients with cancer are surgery, radiation, and drug therapy, including chemotherapy,
hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, immunotherapy, and cell-based therapy, used alone or
in combination to enhance efficacy. Our CER-T cell therapy candidates, if any are approved, may not